(Q34699509)

4 August 2017

1 reference

title

Milestones in the treatment of gout (English)

1 reference

4 August 2017

T. Yü

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A4604776

11 February 2023

T. F. Yu

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A4604776

11 February 2023

language of work or name

English

0 references

publication date

1 May 1974

1 reference

full work available at URL

4 August 2017

https://api.elsevier.com/content/article/PII:0002934374906342?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

https://api.elsevier.com/content/article/PII:0002934374906342?httpAccept=text/plain

11 February 2023

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

American Journal of Medicine

11 February 2023

published in

1 reference

4 August 2017

56

1 reference

4 August 2017

5

1 reference

4 August 2017

676-685

1 reference

"STUDIES ON THE NATURE OF GOUTY TOPHI" BY MAX FREUDWEILER, 1899. (AN INFLAMMATORY RESPONSE TO INJECTED SODIUM URATE, 1899). AN ABRIDGED TRANSLATION, WITH COMMENTS.

4 August 2017

1

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Hageman factor and acute gouty arthritis

11 February 2023

4

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

History of the use of colchicum and related medicaments in gout; with suggestions for further research

11 February 2023

6

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Colchicine. Clinical pharmacology in acute gouty arthritis

11 February 2023

7

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

The Biochemical Events of Mitosis. II. The in Vivo and in Vitro Binding of Colchicine in Grasshopper Embryos and Its Possible Relation to Inhibition of Mitosis*

11 February 2023

8

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Colchicine: a common mechanism for its anti-inflammatory and anti-mitotic effects

11 February 2023

9

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Mobilization and extracellular release of granular enzymes from human leukocytes during phagocytosis: inhibition by colchicine and cortisol but not by salicylate

11 February 2023

10

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Direct evidence for a colchicine-induced impairment in the mobility of membrane components

11 February 2023

11

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Colchicine plasma levels. Implications as to pharmacology and mechanism of action

11 February 2023

12

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Ultrastructural Changes in Skeletal Muscle Induced by Colchicine

11 February 2023

13

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Phenylbutazone (butazolidin) in rheumatoid arthritis and gout

11 February 2023

16

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Current principles of management in gout

11 February 2023

17

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Effects of adrenocorticotropic hormone (ACTH) in gout.

11 February 2023

19

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

A METHOD FOR MEASURING SWELLING OF HANDS AND FEET. II. INFLUENCE OF NEW ANTI-INFLAMMATORY DRUG, INDOMETHACIN, IN ACUTE GOUT.

11 February 2023

20

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Current status of the treatment of gout

11 February 2023

24

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

A view of gout as inborn error of metabolism

11 February 2023

26

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Principles of current management of primary gout.

11 February 2023

27

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

The influence of a new benzoic acid derivative on the metabolism of paraaminosalicylic acid (PAS) and penicillin

11 February 2023

28

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

The clinical and metabolic effects of benemid in patients with gout

11 February 2023

32

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Metabolites of probenecid. Chemical, physical, and pharmacological studies

11 February 2023

34

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Mobilization of gouty tophi by protracted use of uricosuric agents

11 February 2023

35

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Therapeutic value of probenecid (benemid) in gout

11 February 2023

36

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Some observations on 520 gouty patients

11 February 2023

38

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

11 February 2023

Benemid

39

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Evaluation of uricosuric agents in chronic gout

11 February 2023

40

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Protracted uricosuric therapy in tophaceous gout

11 February 2023

41

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Paradoxical retention of uric acid by uricosuric drugs in low dosage

11 February 2023

42

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Tubular secretion of urate in man.

11 February 2023

43

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Probenecid (benemid); its uses and side-effects in 2,502 patients

11 February 2023

44

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Fatal massive necrosis of the liver as a manifestation of hypersensitivity to probenecid

11 February 2023

45

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Nephrotic syndrome caused by probenecid

11 February 2023

46

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Observations on the antirheumatic and physiologic effects of phenylbutazone (butazolidin) and some comparisons with cortisone

11 February 2023

47

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Biochemical pharmacological considerations of phenylbutazone and its analogues

11 February 2023

49

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Effect of phenylbutazone (3,5 dioxo-1,2-diphenyl-4-n-butylpyrazolidine) on renal clearance of urate and other discrete renal functions in gouty subjects

11 February 2023

50

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

A study of the inverse relationship between pKa and rate of renal excretion of phenylbutazone analogs in man and dog

11 February 2023

52

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Results of a clinical trial of G-28315, a sulfoxide analog of phenylbutazone, as a uricosuric agent in gouty subjects

11 February 2023

53

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Use of the newer uricosuric agents in the management of gout

11 February 2023

54

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Studies of interactions among drugs in man at the renal level: Probenecid and sulfinpyrazone

11 February 2023

55

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

MUTUAL SUPPRESSION OF THE URICOSURIC EFFECTS OF SULFINPYRAZONE AND SALICYLATE: A STUDY IN INTERACTIONS BETWEEN DRUGS

11 February 2023

56

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Metabolic studies of allopurinol, an inhibitor of xanthine oxidase

11 February 2023

59

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Renal clearance of oxipurinol, the chief metabolite of allopurinol

11 February 2023

60

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Observations on the Disposition of Probenecid in Patients Receiving Allopurinol

11 February 2023

61

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

EFFECT OF ALLOPURINOL (4-HYDROXYPYRAZOLO-(3,4-D)PYRIMIDINE) ON SERUM AND URINARY URIC ACID IN PRIMARY AND SECONDARY GOUT

11 February 2023

62

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Urinary Metabolites in Congenital Hyperuricosuria

11 February 2023

63

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Enzyme Defect Associated with a Sex-Linked Human Neurological Disorder and Excessive Purine Synthesis

11 February 2023

64

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Further experiences of toxic epidermal necrolysis incriminating allopurinol, pyrazolone and derivatives

11 February 2023

67

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Aplastic agranulocytosis after allopurinol therapy

11 February 2023

69

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

11 February 2023

Xanthine stone formation

72

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Urinary Xanthine Stones-a Rare Complication of Allopurinol Therapy

11 February 2023

73

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Allopurinol and xanthine nephropathy

11 February 2023

74

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

The renal mechanism for urate excretion in man.

11 February 2023

78

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Uric acid nephrolithiasis in gout. Predisposing factors

11 February 2023

80

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Secondary gout associated with myeloproliferative diseases

11 February 2023

81

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

PREVENTION OF HYPERURICEMIA IN LEUKEMIA AND LYMPHOMA: USE OF ALOPURINOL, A XANTHINE OXIDASE INHIBITOR.

11 February 2023

82

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Use of allopurinol for prevention and control of hyperuricemia in patients with neoplastic disease

11 February 2023

83

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Uric acid nephrolithiasis

11 February 2023

85

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Observations on Dissolution of Uric Acid Calculi

11 February 2023

86

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Clinical Significance of Hyperuricemia in Routinely Screened Hospitalized Men

11 February 2023

87

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Factors affecting urate excretion following diuretic administration in man.

11 February 2023

89

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

The occurrence of hyperuricemia during pyrazinamide-isoniazid therapy

11 February 2023

91

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Hyperuricemia Due to Ethambutol

11 February 2023

92

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Hyperuricemia in primary and renal hypertension

11 February 2023

93

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Hyperuricemia in Diabetic Ketoacidosis

11 February 2023

94

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Hyperuricemia in hypoparathyroidism

11 February 2023

95

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Hyperuricemia in hyperparathyroidism

11 February 2023

96

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Hyperuricemia in myxedema

11 February 2023

97

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Gout and hyperuricemia after adrenalectomy for hypertension

11 February 2023

98

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Hyperuricemia, a concomitant of congenital vasopressin-resistant diabetes insipidus in the adult

11 February 2023

99

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

Clinical survey of 354 patients with gout

11 February 2023

100

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

The clinical detection of the genetic carriers of inherited disease

11 February 2023

101

1 reference

https://api.crossref.org/works/10.1016/0002-9343(74)90634-2

11 February 2023

Identifiers

1 reference

4 August 2017

1 reference